{"disease":{"id":"advanced-or-recurrent-endometrial-cancer","name":"advanced or recurrent endometrial cancer"},"drugs":{"marketed":[{"drug_id":"chembl-chembl3301587","indication_name":"Advanced or Recurrent Endometrial Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06746116","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":45,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05798611","title":"Study of ART0380 in Patients With Biologically Selected Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Artios Pharma Ltd","has_results":false},{"nct_id":"NCT06625515","title":"First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Accent Therapeutics","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}